^
    Back
    Association details:
    Biomarker:MET amplification
    Cancer:Solid Tumor
    Drug:telisotuzumab adizutecan (ABBV-400) (Topoisomerase I inhibitor, c-MET-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

    Excerpt:
    ...- participants with advanced histologically or cytologically confirmed solid tumors characterized by MET amplification who are...
    Trial ID:
    NCT05029882
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2023
    Title:

    691P - Efficacy of ABBV-400 monotherapy in patients with MET gene amplified advanced solid tumors

    Published date:
    10/16/2023
    Excerpt:
    Confirmed partial response observed in 8 pts (ORR = 73%, 95% CI: 39, 94) per investigator review and RECIST v1.1; 6 pts had ongoing response. Median progression-free survival was 10.8 months (95% CI: 1.2, not reached [NR]), duration of response and overall survival NR; longest ongoing response was >9 months....ABBV-400 monotherapy showed promising tolerability and efficacy in pts with various MET amp advanced solid tumors.
    Trial ID:
    NCT05029882